ArticleThe British journal of radiology2022
MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
Article in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Artificial intelligence-assisted reading of non-contrast prostate MRI: application and concordance with expert interpretation in a screening population within the PROSA trial.European radiology · 2026Trial
- Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).European radiology · 2024Trial
- Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.Prostate cancer and prostatic diseases · 2026Article
- Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers · 2026Review
- Is Standard TRUS-Guided Prostate Biopsy the End of the Game?Urology research & practice · 2026Article
- Prostate cancer detection with transrectal in-bore MRI biopsies: impact of prostate volume and lesion features.Insights into imaging · 2025Article
- What the urologist needs to know before radical prostatectomy: MRI effective support to pre-surgery planning.La Radiologia medica · 2024Review
- Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?European radiology · 2023Observational
- Review
- A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide.Journal of clinical medicine · 2023Review
- The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Pathological Accuracy in Prostate Cancer: Single-Center Outcomes of 3 Different Magnetic Resonance Imaging-Targeted Biopsy Techniques and Random Systematic Biopsy.Turkish journal of urology · 2022Article
- Innovations in prostate cancer: introductory editorial.The British journal of radiology · 2022Article
- Imaging of clinically silent rectoprostatic hematoma in MRI guided in-bore prostate biopsy.Scientific reports · 2022Observational
- Concordance of MRI-Guided Fusion and Systematic 12-Core Prostate Biopsy for the Detection of Prostate Cancer.Frontiers in oncology · 2022Article
- Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion.Frontiers in oncology · 2022Article
- TRUS-Guided Target Biopsy for a PI-RADS 3-5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the detection rates of overall prostate cancer (PCa) and clinically significant PCa (csPCa) and the median percentage of cancer per biopsy core between MRI-guided In-bore and MRI-TRUS fusion-targeted biopsy (TBx).
methodsIn this retrospective study, 223 patients who underwent prostate multiparametric MRI (mpMRI) and subsequent MR-directed biopsy were included. For PCa and csPCa detection rate (DR), contingency tables were tested via the Pearson's chi-squared to explore the variance of the outcome distribution. The percentage of cancer per biopsy core was tested with a two-tailed Mann-Withney test.
resultsOne hundred and seventeen and 106 patients underwent MRI-TRUS fusion or MRI In-bore TBx, respectively. 402 MRI biopsy targets were identified, of which 206 (51.2%) were biopsied with the MRI-TRUS TBx and 196 (48.8%) with the MRI In-bore TBx technique. Per-patient PCa and csPCa detection rates were 140/223 (62.8%) and 97/223 (43.5%), respectively. PCa-DR was 73/117 (62.4%) and 67/106 (63.2%) for MRI-TRUS and MRI In-Bore TBx (
conclusionNo statistically significant difference in the detection rate of MRI In-bore and MRI-TRUS fusion TBx was found. MRI In-bore TBx showed higher per-core percentage of malignant cells. ADVANCES IN KNOWLEDGE: MRI In-bore biopsy might impact risk stratification and patient management considering the higher per-core percentage of malignant cells, especially for patients eligible for active surveillance or focal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.